secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001104659-23-072950
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm appoints Nir Naor as Board member and Audit Committee chair; Taub resigns
--------------------------------------------------------------------------------

- Malcolm Taub resigned from Board effective June 15, 2023; decision not due to any disagreement with the Company.
- Nir Naor elected to Board effective June 20, 2023, as new independent director, Audit Committee chair, and GNC Committee member.
- Naor receives initial grant of 11,999 restricted shares plus annual stock option or restricted stock awards, vesting monthly over 12 months.
- Naor has over 20 years of finance and biotech experience, including CFO of Arbor Pharmaceuticals and senior roles at UCB and AstraZeneca.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923072950/0001104659-23-072950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923072950/tm2319248d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-072950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer